Gallbladder Adenocarcinoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Gallbladder Adenocarcinoma

View Main Condition: Gallbladder Cancer

What is the definition of Gallbladder Adenocarcinoma?
Gallbladder adenocarcinoma is a type of cancer that starts in gland-like cells that line the gallbladder. The gallbladder is a small pear-shaped organ below the liver that stores bile, which is a digestive fluid.
What are the symptoms of Gallbladder Adenocarcinoma?
Gallbladder adenocarcinoma may not have any symptoms until the late stages of the disease. Symptoms of gallbladder adenocarcinoma may include nausea and vomiting, loss of appetite, fever, abdominal bloating, abdominal pain in the right upper side, abdominal lumps, unexplained weight loss, itchy skin, dark urine, pale or greasy stools, and yellowing of the whites of the eyes and skin.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Gallbladder Adenocarcinoma?
Treatment for gallbladder adenocarcinoma depends on the stage, or how far it has progressed. Treatments for gallbladder adenocarcinoma include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.
Who are the top Gallbladder Adenocarcinoma Local Doctors?
Elite in Gallbladder Adenocarcinoma
Elite in Gallbladder Adenocarcinoma
Referral may be required

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

I enjoy traveling, dancing and food. Dr. Shroff is rated as an Elite provider by MediFind in the treatment of Gallbladder Adenocarcinoma. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.

Elite in Gallbladder Adenocarcinoma
Surgical Oncology
Elite in Gallbladder Adenocarcinoma
Surgical Oncology
Referral may be required

Ohio State Martha Morehouse Outpatient Care

2050 Kenny Rd, 
Columbus, OH 
Languages Spoken:
English
Offers Telehealth

Timothy Pawlik is a Surgical Oncologist practicing medicine in Columbus, Ohio. Dr. Pawlik is rated as an Elite provider by MediFind in the treatment of Gallbladder Adenocarcinoma. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Gallbladder Adenocarcinoma, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Gallbladder Adenocarcinoma
General Surgery | Transplant Surgery
Advanced in Gallbladder Adenocarcinoma
General Surgery | Transplant Surgery
Referral may be required

Texas Health Surgical Specialists

1325 Pennsylvania Ave, Ste 560, 
Fort Worth, TX 
Experience:
17+ years
Languages Spoken:
English

Dr. Kimberly Washington is fellowship-trained in hepato-pancreato-biliary surgery with vast experience in the surgical and non-surgical treatment of liver, pancreas and biliary tract disorders. She uses a variety of techniques, including minimally invasive laparoscopy, endoscopy, ablation and robotic-assisted approaches, in the management of benign pancreatic masses, acute/chronic pancreatitis and pancreatic cysts. She is also trained in the management of hepatocellular carcinoma, cholangiocarcinoma and all liver metastatic diseases. Additionally, she treats benign diseases of the liver and biliary tract, including hepatic adenomas, liver hemangiomas, polycystic liver disease, simple and complex biliary stone disease, and bile duct injuries.Dr. Washington earned her medical degree and completed general surgery residency at the University of Tennessee in Memphis. She then served the Arlington, Texas community as a board-certified general surgeon from 2014 until 2020. In 2020, she returned to training in hepato-pancreato-biliary surgery fellowship at Oregon Health & Science University in Portland.In addition to her dedication to the management of surgical disease, Dr. Washington has also served on a global scale, caring for patients in India, Peru, Guatemala and Kenya. She has and continues to serve on numerous regional and national committees to advance the treatment of hepato-pancreato-biliary diseases. Dr Washington has published peer-reviewed works on areas of special interest, including multi-disciplinary management of colorectal liver metastasis with node-negative primary disease and surgical management of breast cancer liver metastasis, presenting many of these published works at national and international meetings. Through her role as a faculty member with the TCU Burnett School of Medicine, Dr. Washington was recognized in 2024 with the Gachman Endowed Faculty Excellence Award. She is a member of the American College of Surgeons, Americas Hepato-Pancreato-Biliary Association, American Pancreatic Association, Association of Women Surgeons, International Hepato-Pancreato-Biliary Association, Society of Surgical Oncology and Society for Surgery of the Alimentary Tract. Dr. Washington is rated as an Advanced provider by MediFind in the treatment of Gallbladder Adenocarcinoma. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Familial Pancreatic Cancer, Pancreatic Cancer, Pancreatic Pseudocyst, Pancreatectomy, and Liver Embolization.

What are the latest Gallbladder Adenocarcinoma Clinical Trials?
Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma

Summary: Gallbladder adenocarcinoma is a devastating disease associated with a poor prognosis. Gallbladder and other biliary cancers will be responsible for an estimated 11,980 new cases, and 4,090 deaths in the US during 2020. The 5-year survival for all patients with gallbladder cancer is 18%, however this plummets to 2% for patients with metastatic disease. Patients with gallbladder cancer frequently de...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Summary: This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.